Delta 4

Delta 4 is a drug discovery and development company that combines in silico drug discovery and big data analysis with extensive expertise in molecular biology and clinical development to create a powerful proprietary drug discovery platform. This platform generates promising drug candidates annotated with biological and medical information, enabling rapid establishment of clinical proof-of-concept. The company focuses on discovering new indications for approved drugs (drug repurposing). In its first therapeutic area, focal segmental glomerulosclerosis (FSGS), a devastating kidney disease with high and urgent medical needs, Delta 4 has identified and preclinically validated promising drug candidates, which are now being prepared for clinical proof-of-concept. In 2020, the company applied its drug discovery platform to other indications. As a result, Delta 4 has prepared a potential COVID-19 therapy for Phase 1 development and filed four patents for compounds targeting two indications.